Form4insider filings, from the source

SEC Form 4 · accession 0001325812-16-000080

ALNYLAM PHARMACEUTICALS, INC. · ALNY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
John Maraganore
Officer — Chief Executive Officer · Director
Period of report
Apr 19, 2016
Accepted (ET)
Apr 21, 2016 · 5:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockApr 19, 2016M15,076$22.75A148,465D
Common StockF2Apr 19, 2016S9,371$67.0187D139,094D
Common StockF3Apr 19, 2016S5,405$68.0028D133,689D
Common StockF4Apr 19, 2016S300$68.7067D133,389D
Common StockApr 20, 2016M15,075$22.75A148,464D
Common StockF5Apr 20, 2016S12,670$67.3753D135,794D
Common StockF6Apr 20, 2016S2,405$68.2444D133,389D
Common StockF7holding———2,750Iby Managed Account

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F8$22.75Apr 19, 2016M15,076A—Dec 14, 2016Common Stock15,07675,377D
Stock Option (right to buy)F8$22.75Apr 20, 2016M15,075A—Dec 14, 2016Common Stock15,07560,302D

Explanation of responses